The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non–muscle invasive bladder cancer

Harsanyi, Stefan; Žiaran, Stanislav; Bevizova, Katarina; Nováková, Zuzana; Trebatický, B.; Bujdák, Peter; Galbavý, Š; Danišovič, Ľuboš

doi:10.4149/bll_2020_072

Cited by 4 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent series of 342 NMIBC, patients with high expression levels of E-cadherin showed a better OS compared to patients with low and intermediate expression ( p = 0.001), although no association with recurrence was found ( 32 ).…”

Section: Prognostic Biomarkers In Nmibcmentioning

confidence: 98%

Non-muscle invasive bladder cancer biomarkers beyond morphology

et al. 2022

View full text Add to dashboard Cite

Non-muscle invasive bladder cancer (NMIBC) still represents a challenge in decision-making and clinical management since prognostic and predictive biomarkers of response to treatment are still under investigation. In addition to the risk factors defined by EORTC guidelines, histological features have also been considered key variables able to impact on recurrence and progression in bladder cancer. Conversely, the role of genomic rearrangements or expression of specific proteins at tissue level need further assessment in NMIBC. As with muscle-invasive cancer, NMIBC is a heterogeneous disease, characterized by genomic instability, varying rates of mutation and a wide range of protein tissue expression. In this Review, we summarized the recent evidence on prognostic and predictive tissue biomarkers in NMIBC, beyond morphological parameters, outlining how they could affect tumor biology and consequently its behavior during clinical care. Our aim was to facilitate clinical evaluation of promising biomarkers that may be employed to better stratify patients. We described the most common molecular events and immunohistochemical protein expressions linked to recurrence and progression. Moreover, we discussed the link between available treatments and molecular drivers that could be predictive of clinical response. In conclusion, we foster further investigations with particular focus on immunohistochemical evaluation of tissue biomarkers, a promising and cost-effective tool for daily practice.

show abstract

Section: Prognostic Biomarkers In Nmibcmentioning

confidence: 98%

Non-muscle invasive bladder cancer biomarkers beyond morphology

et al. 2022

View full text Add to dashboard Cite

show abstract

“…a group of cadherins: E-cadherin, N-Cadherin, and P-Cadherin (31)(32). Other studied biomarkers in urogenital tumours (including RCC) are the markers associated with CD8 + T-lymphocytes, p53 a Ki-67 (34)(35)(36)(37).…”

Section: U N C O R R E C T E Dmentioning

confidence: 99%

Renal cell carcinoma – summarizing overview, biomarkers, metastases and new perspectives

Dovalova¹,

Rybar²,

Faloughy³

et al. 2022

BLL

View full text Add to dashboard Cite

Kidney carcinoma is currently the tenth most diagnosed tumour in women and the sixth in men. It makes up about 4 % of all malignant tumours. In urology, it is the third most common malignant disease. It is most often diagnosed between the ages of 40 and 60, and its incidence is still rising. Risk factors include: positive family history, high blood pressure, obesity, and smoking. In examining the samples of cancer tissues, histopathological examination methods were used, including biomarkers such as: LRRC3B, TCF21, or cadherins and other markers. The use of imaging methods such as computer tomography and sonography improved the detection ability of an asymptomatic kidney tumour. Due to the expansion of diagnostic methods and the introduction of new techniques in surgical treatment, the paradigm in the surgical treatment of this disease has changed in recent years. In the case of a detailed study of the intracellular structures in the carcinogenic processes, the more profound knowledge about them can lead to the elimination of the need for surgical resection in future (Tab. 7, Fig. 4, Ref. 51).

show abstract

“…Bladder cancer is the most common malignancy involving the urinary system, and the 10th most common malignancy overall 1 with a rising incidence worldwide. 2 Transitional cell carcinoma is the predominant histological type, accounting for approximately 90% of all bladder cancers. Transitional cell carcinoma also affects the renal pelvis, ureter or urethra as all are lined with transitional cell urothelium.…”

Section: Introductionmentioning

confidence: 99%

⁸⁹Zirconium-labelled girentuximab (⁸⁹Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma

et al. 2022

View full text Add to dashboard Cite

IntroductionBladder cancer is a lethal disease with a rising incidence on a background of limited conventional imaging modalities for staging (either CT of the chest-abdomen-pelvis or 18F-fluorodeoxyglucose positron emitting tomography (FDG-PET/CT)). CT is known to have relatively low sensitivity for detecting low volume metastatic disease, an important goal when considering surgical interventions entailing significant potential morbidity. FDG is also limited, being predominantly renally excreted and, therefore, producing intense non-specific activity in the urinary tract, which limits its utility to detect bladder and upper tract lesions, or nodal metastases in close proximity to the urinary tract. 89Zirconium-labelled girentuximab (89Zr-TLX250) may have utility in the accurate staging of bladder and urothelial carcinomas, with less renal excretion as compared with FDG; however, this has not previously been investigated.Methods and analysis89Zirconium-labelled girentuximab PET in Urothelial Cancer Patients is a single-arm phase I trial examining the feasibility of using 89Zr-TLX250-PET/CT as a staging modality for urothelial and bladder carcinomas by examining isotope uptake by the cancer. This trial will also examine the safety and utility of 89Zr-TLX250-PET/CT in patients either undergoing preoperative staging of bladder or other urothelial carcinomas for curative intent, or with known metastatic urothelial carcinomas. All participants will undergo 89Zr-TLX250-PET/CT and will need to have undergone recent FDG-PET/CT for comparison. This trial aims to recruit 10 participants undergoing preoperative staging and 10 participants with known metastatic disease. The primary endpoint is feasibility defined by the ability to recruit to the target sample size within the study duration; secondary endpoints are safety, tolerability, sensitivity and specificity in detecting lymph node metastases compared with FDG-PET/CT.Ethics and disseminationEthics approval has been obtained from the South Metropolitan Health Service Human Research Ethics Committee (RGS0000003940). Eligible patients will only be enrolled after providing written informed consent. Patients will be given a full explanation, in lay terms, of the aims of the study and potential risks including as a written patient information sheet.Trial registration numbersACTRN12621000411842, NCT05046665.

show abstract

The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non–muscle invasive bladder cancer

Cited by 4 publications

References 26 publications

Non-muscle invasive bladder cancer biomarkers beyond morphology

Non-muscle invasive bladder cancer biomarkers beyond morphology

Renal cell carcinoma – summarizing overview, biomarkers, metastases and new perspectives

⁸⁹Zirconium-labelled girentuximab (⁸⁹Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma

Contact Info

Product

Resources

About

The prognostic value of E-cadherin and Ki-67 compared to standard histopathologic examination in non–muscle invasive bladder cancer

Cited by 4 publications

References 26 publications

Non-muscle invasive bladder cancer biomarkers beyond morphology

Non-muscle invasive bladder cancer biomarkers beyond morphology

Renal cell carcinoma – summarizing overview, biomarkers, metastases and new perspectives

89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma

Contact Info

Product

Resources

About

⁸⁹Zirconium-labelled girentuximab (⁸⁹Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma